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Role of altered renal lipid metabolism and the sterol regula-
tory element binding proteins in the pathogenesis of age-related
renal disease.
Background. There are well-known changes in age-related
renal function and structure, including glomerulosclerosis and
decline in glomerular filtration rate (GFR). The purpose of this
study was to identify a potential role for lipids in mediating
age-related renal disease.
Methods. Mice of five different age groups (3, 6, 12, 19, and
23 months old) were studied.
Results. We have found that in C57BL/6 mice there was a
progressive increase in age-related glomerulosclerosis [increase
in periodic acid-Schiff (PAS) staining and accumulation of
extracellular matrix proteins including type IV collagen and
fibronectin], increased glomerular basement thickness and
podocyte width and effacement, and increased proteinuria.
These changes were associated with age-related increase in lipid
accumulation as determined by increased Oil Red O staining in
kidney sections. Biochemical analysis indicated that these lipid
deposits corresponded to significant increases in renal triglyc-
eride and cholesterol content. We have also found significant
age-related increases in the nuclear transcription factors, sterol
regulatory element-binding proteins (SREBP-1 and SREBP-2),
protein abundance and increased expression or activity of their
target enzymes that play an important role in lipid synthesis.
Conclusion. Our results indicated that there was an age-
related increase in renal expression of SREBP-1 and SREBP-2
with resultant increases in lipid synthesis and triglyceride and
cholesterol accumulation in the kidney. Because we have previ-
ously shown that increased expression of SREBPs in the kidney
per se results in glomerulosclerosis and proteinuria, our data
suggested that increased SREBPs’ expression resulting in in-
creased renal lipid accumulation may play an important role in
age-related nephropathy.
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lar basement membrane thickness, podocyte width.
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The normal aging process in humans and in experimen-
tal animals is associated with decreases in renal blood
flow (RBF), glomerular filtration rate (GFR), glomeru-
losclerosis, and alterations in tubular function, including
functionally important defects in concentration, dilution,
acidification, and phosphate transport. Recent data from
the Third National Health and Nutrition Examination
Survey (NHANES III) indicate that in addition to di-
abetes and hypertension, age is also a major predictor
of chronic kidney disease (CKD), which is characterized
by decline in kidney function (GFR less than 60 mL/
min/1.73 m2) and presence of kidney damage (albu-
minuria). The incidence of CKD increases as a func-
tion of age and 15% of individuals older than 65 years
without concomitant hypertension or diabetes have
CKD [1].
During disease states the decreases in RBF and GFR
become of major clinical significance as they interfere
with normal drug excretion and predispose the elderly
to increased incidence of ischemic and toxic acute renal
failure [2]. In addition, the age-related glomerulosclerosis
and tubulointerstitial fibrosis predispose the elderly to a
progressive decline in renal function caused by diabetes
mellitus, hypertension, and other systemic diseases as-
sociated with glomerulosclerosis. Furthermore, presence
of CKD results in major complications such as anemia,
bone disease, and malnutrition, and CKD is definitely a
major independent risk factor for cardiovascular disease
and all-cause mortality [3].
The elderly are at least five times more prone to de-
velop end-stage renal disease (ESRD) than young adults
[1]. Both European and United States registries high-
light the growing incidence of elderly subjects initiating
dialysis [4, 5]. Increasing prevalence of renal disease in
a growing elderly population necessitates understanding
the anatomic, physiologic, and pathologic mechanisms in-
volved in the aging kidney.
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Age-related glomerulosclerosis and tubulointerstitial
fibrosis with loss of GFR may not necessarily be
irreversible consequences of aging. Interestingly, longi-
tudinal follow up of 254 healthy elderly subjects over
23 years old with repeated creatinine clearances revealed
that one third of the subjects had no absolute age-related
decrease in creatinine clearance [6]. Similarly, studies per-
formed mainly in rodents suggested that glomeruloscle-
rosis and tubulointerstitial fibrosis are not necessarily
inevitable consequences of the aging process, that sev-
eral factors, including angiotensin II [7], advanced glyco-
sylation end products [8], oxidative stress [9], and nitric
oxide [10], may play a role in age-related renal disease
and that modulation of these processes may help prevent
or at least attenuate the age-related increase in glomeru-
losclerosis and decline in renal function.
Several of the above metabolic and cellular processes
that modulate age-related glomerulosclerosis are re-
markably similar to metabolic and cellular processes that
play an important role in the pathogenesis and pro-
gression of kidney disease in diabetes mellitus [11–14].
In recent studies we found that in a model of type 1
diabetes in the rat there was increased renal accumula-
tion of lipids which was mediated by increased expres-
sion of the sterol regulatory element-binding protein-1
(SREBP-1). In cultured mesangial cells high glucose
medium also stimulated increased expression of SREBP-
1 and in SREBP-1a transgenic mice, in the absence of
any increases in serum glucose or serum lipids, there was
increased accumulation of triglyceride and cholesterol
in the kidney which was associated with increased ex-
pression of transforming growth factor-b (TGF-b) and
vascular endothelial growth factor (VEGF), and the
extracellular matrix proteins type IV collagen and fi-
bronectin, resulting in glomerulosclerosis and protein-
uria [15]. This study indicated that increased expression
of SREBP-1 plays an important role in the pathogenesis
of diabetic kidney disease.
The SREBP has been described as a master regulator
of both fatty acid and cholesterol metabolism [16, 17].
Three SREBP isoforms have been identified and charac-
terized, SREBP-1a, SREBP-1c, and SREBP-2. Studies in
transgenic mice overexpressing each of the three SREBP
isoforms in the liver have indicated that SREBP-1c plays
a preferential role in fatty acid synthesis compared to
cholesterol synthesis, whereas SREBP-2 plays a prefer-
ential role in cholesterol synthesis compared to fatty acid
synthesis [16, 17].
In view of the similarities between mediators of age-
related and diabetes-induced glomerulosclerosis, we per-
formed the present study to determine if age-related
glomerulosclerosis was associated with increased renal
expression of SREBPs with resultant increased accumu-
lation of lipids in the kidney.
METHODS
Animal models
We obtained 3-month-old, 6-month-old, 12-month-old,
19-month-old, and 23-month-old male C57BL/6 mice (18
in each group) from the NIA aging colony, and housed
them at the animal facility at the Denver Veterans Affairs
Medical System. The mice were maintained on a 12-hour
light/dark cycle and fed standard rodent chow (Purina
rodent chow 5015) (Ralston Purina Co., St. Louis, MO,
USA) ad libitum.
Spot urine samples were obtained on all mice. After
the urine collection, 12 mice in each age group were sac-
rificed by intraperitoneal injection of pentobarbital. One
kidney was freeze-clamped in liquid nitrogen for sub-
sequent (1) RNA extraction and quantitative real-time
polymerase chain reaction (PCR), (2) measurement of
enzyme activity, (3) measurement of lipid composition,
and (4) Western blotting. The other kidney was homoge-
nized as described below for isolation of nuclei.
In order to eliminate the confounding variable of dif-
ferent dietary status between animals on some of the
measured variables, one group of mice (N = 6) were sac-
rificed after a 48-hour fasting and another group of mice
(N = 6) after a 48-hour fasting followed by 4 hours of
refeeding.
In addition, six mice in each age group under-
went in vivo perfusion fixation and the kidneys were
then processed for histologic stains, immunofluores-
cence microscopy, and electron microscopy as described
below.
Blood and urine chemistries
Serum glucose was analyzed using the glucose C2 Kit
(Wako Chemicals USA, Inc., Richmond, VA, USA) [18].
Serum cholesterol was analyzed using the cholesterol CII
Kit (Wako Chemicals USA, Inc.) [19]. Serum triglyc-
erides were determined by the L Type TG H Kit (Wako
Chemicals USA, Inc.) [20]. Serum free fatty acids were
determined using the NEFA C Kit (Wako Chemicals
USA, Inc.) [21]. Serum creatinine concentration was de-
termined by the Jeffe’s reaction of alkaline picrate with
creatinine via the Creatinine Companion Kit (Exocell,
Philadelphia, PA, USA) [22]. Blood urea nitrogen (BUN)
was analyzed using the L-Type UN Kit (Wako Chemi-
cals USA, Inc.) based on enzymatic assay utilizing urease
and glutamate dehydrogenase. Urine albumin concen-
tration was determined by competitive enzyme-linked
immunosorbent assay (ELISA) via the Albuwell M Kit
(Exocell) per the manufacturer’s protocol. Urine creati-
nine was analyzed using the same kit as serum creatinine.
Results were expressed as the urine albumin to creatinine
ratio (mg/g).
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Homogenate and nuclei isolation
Kidneys were homogenized at 4◦C in homogenization
buffer [20 mmol/L Tris-HCl, pH 7.4, 75 mmol/L NaCl,
2 mmol/L ethyleneglycol tetraacetate (EGTA), 2 mmol/L
ethylenediaminetetraacetic acid (EDTA), 1 mmol/L
Na3VO4, and 1 mmol/L dithiothreitol (DTT)], supple-
mented with a protease inhibitor cocktail consisting of
104 mmol/L AEBSF, 0.08 mmol/L aprotinin, 2 mmol/L
leupeptin, 4 mmol/L bestatin, 1.5 mmol/L pepstatin A,
and 1.4 mmol/L E-64 (Sigma-Aldrich, St. Louis, MO,
USA).
Nuclear extracts were prepared according to the
method of Morooka et al [23] with minor modifications.
An aliquot of the homogenate was centrifuged at 3300 ×
g for 15 minutes at 4◦C. The supernatants were discarded
and the packed nuclear volume was estimated. The nu-
clei were resuspended in 0.5 packed nuclear volume of
low-salt buffer [20 mmol/L Hepes, pH 7.9, 25% glycerol,
1.5 mmol/L MgCl2, 20 mmol/L KCl, 0.2 mmol/L EDTA,
0.2 mmol/L phenylmethylsulfonyl fluoride (PMSF), and
0.5 mmol/L DTT]. A 0.5 packed nuclear volume of high-
salt buffer (20 mmol/L Hepes, pH 7.9, 25% glycerol,
1.5 mmol/L MgCl2, 0.8 mol/L KCl, 0.2 mmol/L EDTA,
0.2 mmol/L PMSF, and 0.5 mmol/L DTT) was then added.
After 30 minutes of continuous gentle mixing, the nuclei
were pelleted by centrifugation (30 minutes at 25,000 ×
g). The supernatants were saved and the protein concen-
tration was determined by the method of Lowry et al [24].
The nuclear extracts were stored at −80◦C.
Protein electrophoresis and Western blotting
Nuclear extracts were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
(10% wt/vol), as described by Laemmli [25] and then
transferred to nitrocellulose membranes. Membranes
were blocked in 5% dried milk in TBST [0.2% Tween-
20 in 1× Tris-buffered saline (TBS)], incubated with (1)
anti-SREBP-1 or (2) anti-SREBP-2 (1:1000) (BD Bio-
sciences, Pharmingen, San Jose, CA, USA) antibodies
followed by horseradish peroxidase–labeled anti-mouse
IgG (1:5000 dilution) (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA), washed four times with 1×
TBS, and then developed using the chemiluminescence
detection system (Pierce Biotechnology, Rockford, IL,
USA). The signals were quantified in a Phosphor Im-
ager with chemiluminescence detector and densitometry
software (Bio-Rad Laboratories, Hercules, CA, USA).
Kidney homogenates were similarly subjected to SDS-
PAGE and then transferred to nitrocellulose membranes.
The membranes were then probed with anti-3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase
(1:500) (Upstate Biotechnology, Lake Placid, NY, USA)
antibody followed by horseradish peroxidase–labeled an-
tirabbit IgG (1:5000 dilution; Molecular Probes, Inc.,
Eugene, OR, USA) and processed as above.
Lipid extraction and analysis
Total lipid was extracted from kidney using the method
of Bligh and Dyer [26]. Total cholesterol and triglyc-
erides were determined using enzyme assays as described
above.
Enzyme activity assay
Adenosine triphosphate (ATP) citrate lyase activity
[27] was determined as described by Corrigan and Rider
[28]. The assay solution, in a final volume of 1.00 mL,
consisted of 50 mmol/L Tris-HCl, pH 7.8, 10 mmol/L
MgCl2, 100 mmol/L KCl, 5 mmol/L ATP, 0.2 mmol/
L coenzyme A, 20 mmol/L potassium citrate, 0.15 mmol/L
nicotinamide adenine dinucleotide (NADH), 10 mmol/L
DTT, 2 U malate dehydrogenase, and kidney homogenate
sample. Assays were preincubated for 7 minutes at 37◦C
and the reaction was started by the addition of coenzyme
A. The decrease in absorbance at 340 nm was measured
in a Varian-Cary 100 Bio UV-Vis Spectrophotometer
(Varian, Palo Alto, CA, USA).
RNA extraction and quantitative real-time PCR
Total RNA was isolated from kidney using TRI-
zol (Invitrogen, Carlsbad, CA, USA) and cDNA was
synthesized using reverse transcript reagents (Bio-Rad
Laboratories). The mRNA level was quantified using
Bio-Rad iCyCler Real Time PCR system. Briefly, 25 lL
total reaction mix contained 20 ng of reverse-transcribed
cDNA, 100 nmol/L forward/reverse primers and 1× iQ
Supermix (Bio-Rad Laboratories). Cyclophilin was used
as internal control and the amount of RNA was calcu-
lated by the comparative CT method as recommended
by the manufacturer. All the data were calculated from
triplicate reactions. The sequences used were indicated
in Table 1.
Perfusion fixation of mouse kidney
Mice were anesthetized and perfused with a fixative
buffer that consisted of 3% paraformaldehyde and 0.05%
picric acid in a 6:4 mixture of cacodylate buffer (pH 7.4,
adjusted to 300 mosmol with sucrose) and 10% hydrox-
yethyl starch. After 5 minutes of fixation, the mice were
perfused for an additional 5 minutes with the cacodylate
buffer [15].
Periodic acid-Schiff (PAS) and Oil Red O staining and
immunofluorescence microscopy
Paraffin sections were stained for hematoxylin and
eosin and PAS. Frozen sections were used for Oil Red
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Table 1. Primers for real-time polymerase chain reaction (PCR)
Forward Reverse
Cyclophilin TGGAGAGCACCAAGACAGACA TGCCGGAGTCGACAATGAT
SREBP-1c GGCACTAAGTGCCCTCAACCT GCCACATAGATCTCTGCCAGTGT
ACO GGCCAACTATGGTGGACATCA ACCAATCTGGCTGCACGAA
CPT-1 ATCATGTATCGCCGCAAACT CCATCTGGTAGGAGCACATGG
HMG-CoA reductase AGCCGAAGCAGCACATGAT CTTGTGGAATGCCTTGTGATTG
ABCA-1 CGTTTCCGGGAAGTGTCCTA GCTAGAGATGACAAGGAGGATGGA
SR-B1 GTTGGTCACCATGGGCCA CGTAGCCCCACAGGATCTCA
LDL receptor GAAGTCGACACTGTACTGACCACC CTCCTCATTCCCTCTGAAAGCCAT
Abbreviations are: ACO, acetyl coenzyme A oxidase; CPT-1, carnitine palmitoyltransferase I; HMG-CoA reductase, 3-hydroxy-3-methylglutaryl coenzyme A
reductase; ABCA1, ATP-binding cassette A-1; SR-B1, scavenger-receptor class B, type 1; LDL receptor, low-density lipoprotein receptor.
O staining to determine the renal accumulation of neu-
tral fats. The stained kidney sections were imaged with an
Olympus microscope and scored semiquantitatively in a
blinded manner by the renal pathologist (M.S.L.).
For immunofluorescence microscopy, frozen sections
were preincubated for 10 minutes at room temperature
with 3% milk powder in phosphate-buffered saline (PBS)
containing 0.05% Triton X-100. They were then cov-
ered overnight at 4◦C with the type IV collagen or fi-
bronectin antibody (Chemicon, Temecula, CA, USA)
diluted 1:200 in the preincubation solution. The sec-
tions were rinsed three times with PBS before incu-
bation for 1 hour at 4◦C with the secondary antibody,
goat antirabbit IgG conjugated to Alexa 488 (Molecu-
lar Probes, Inc.). After rinsing with PBS, the sections
were mounted using Dako-GlycergelTM (Dakopatts,
Glostrup, Denmark) plus 2.5% 1,4-diazabicyclo-{2.2.2}-
octane (DABCO) (Sigma-Aldrich) as a fading retar-
dant. The kidney sections were then imaged with a laser
scanning confocal microscope (Zeiss LSM 510; Zeiss,
Thornwood, NY, USA).
Electron microscopy
Tissue was fixed in 3% paraformaldehyde in a 6:4 mix-
ture of cacodylate buffer (pH 7.4, adjusted to 300 mosmol
with sucrose) and 10% hydroxyethyl starch. The tissue
was then postfixed in 1% buffered osmium tetraoxide.
The sample was dehydrated in a graded series of ethanol
and embedded in an epoxy resin. Tissue was surveyed
with a series of 1 lm sections for a representative sam-
ple. The selected specimens were thin sectioned, viewed,
and photographed with a Phillips electron microscope
201 (Phillips Electron Optics, Inc., Mahwah, NJ, USA).
The sections were read by the renal pathologist (M.S.L.)
in a blinded fashion for determination of basement mem-
brane thickness and podocyte morphology.
Statistical analysis
The results were expressed as mean ± SEM. The
statistical significance of differences was assessed by
one-way analysis of variance (ANOVA) with post hoc
analysis with Student-Newman-Keuls test for multiple
comparisons.
RESULTS
Body weights, kidney weights, and serum chemistries
Table 2 showed the body weights, kidney weights, and
kidney weight/body weight ratio of the mice. As expected,
the older mice weighed more and had larger kidneys.
There was no significant difference in the kidney weight
to body weight ratio. Table 3 showed serum values for
glucose, triglycerides, cholesterol, and free fatty acids for
the mice of various ages. Although there were signifi-
cant changes in fasting versus postprandial serum glu-
cose, triglycerides, cholesterol, and free fatty acids, there
were no significant age-related changes in the serum val-
ues. Table 4 showed serum values for creatinine and
BUN. There were no significant age-related changes in
them.
Aging was associated with increases in glomerular PAS
staining, glomerular basement membrane thickness,
increased podocyte width and effacement, increased
accumulation of extracellular matrix proteins,
and proteinuria
An age-related increase in PAS staining was observed,
which was most evident in mice 12 months and older
(Fig. 1). Electron microscopy of the same kidneys showed
that there was an age-related increase in glomerular base-
ment thickness (Figs. 2 and 3A), and podocyte width
(Figs. 2 and 3B). Podocyte effacement was also more
prominent in the oldest animals, with some 23-month-old
mice showing up to 80% effacement (Fig. 2). Immunoflu-
orescence microscopy revealed that the increase in PAS
staining was associated with age-related increases in type
IV collagen (Fig. 4) and fibronectin (Fig. 5) accumulation.
These glomerular structural changes were associated with
a significant increase in urinary albumin excretion in
23-month-old mice (Fig. 6).
Aging was associated with increases in renal triglyceride
and cholesterol content
There was an age-related increase in Oil Red O stain-
ing which started to become evident at 12 months of
age (Fig. 7) and was indicative of neutral lipid accumula-
tion. The increased Oil Red O accumulation was within
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Table 4. Blood urea nitrogen (BUN) and serum creatinine
3 months old 12 months old 23 months old
BUN mg/dL 31.73 ± 2.77 34.37 ± 2.08 33.70 ± 1.83
Serum creatinine 0.25 ± 0.05 0.26 ± 0.04 0.29 ± 0.05
mg/dL
Values reported as mean ± SEM of six samples.
the glomerular mesangial cells. In addition, there was fo-
cal accumulation of staining in the proximal tubule cells
(Fig. 7C and E), but this was not nearly as dramatic as that
occurring in the glomerulus. The increase in Oil Red O
accumulation corresponded to the increases in mesangial
matrix protein accumulation.
Renal lipid composition studies indicated age-related
increases in triglyceride (Fig. 8) and cholesterol (Fig. 9)
content. These lipid compositional changes were seen
both in 48-hour fasting mice (Figs. 8A and 9A) as well
as in mice that were refed for 4 hours after the 48-hour
fasting (Figs. 8B and 9B).
Aging was associated with increased SREBP-1 and
SREBP-2 expression
Because SREBP-1 and SREBP-2 are the master tran-
scriptional regulators of triglyceride and cholesterol
synthesis, respectively, we next determined whether the
age-related increases in renal triglyceride and choles-
terol content were associated with increased expression
of SREBP-1 and SREBP-2. Western blots of nuclear
extracts from the kidney indicated that in both fasting
(Figs. 10A and 11A) and refed (Figs. 10B and 11B) mice
there were marked and significant increases in SREBP-1
(Fig. 10) and SREBP-2 (Fig. 11) protein abundance.
Aging was associated with increased expression of key
enzymes that mediate fatty acid and cholesterol synthesis
The increase in nuclear SREBP-2 protein abundance
was paralleled with significant increases in HMG-CoA
reductase protein abundance (Fig. 12), a SREBP-2 regu-
lated enzyme that plays a key role in cholesterol synthe-
sis, and low-density lipoprotein (LDL) receptor mRNA
level (Table 5), a SREBP-2 regulated receptor that plays
a key role in cholesterol uptake. We also examined the
age-dependent regulation of two key proteins that me-
diate cholesterol efflux. While there was no change in
scavenger-receptor class B, type 1 (SR-B1) mRNA, there
was an age-related increase in ATP-binding cassette A-1
(ABCA1) mRNA level (Table 5).
The increase in nuclear SREBP-1 protein abundance
was paralleled with a significant increase in ATP cit-
rate lyase activity (Fig. 13), a SREBP-1 regulated en-
zyme that plays an important role in fatty acid synthesis.
The increase in ATP citrate lyase activity was evident at
12 months of age. After 12 months, the level of activity
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Fig. 1. Periodic acid-Schiff (PAS) staining of
kidney cortex of 3-month-old (A), 6-month-
old (B), 12-month-old (C), 19-month-old (D),
and 23-month-old (E) mice. There was an age-
associated increase in matrix accumulation,
which was most evident after 12 months of
age.
Fig. 7. Oil Red O staining for 3-month-
old (A), 6-month-old (B), 12-month-old (C),
19-month-old (D), and 23-month-old (E)
mice. The staining revealed increased ac-
cumulation of lipids (arrows) starting at
12 months, and becoming much more promi-
nent in the 23-month-old mice.
for ATP citrates lyase plateaued, and seemed to mildly
decrease again at 23 months of age. We also examined
the age-dependent regulation of two key proteins that
mediate fatty acid oxidation. There were no age-related
significant changes in acetyl coenzyme A oxidase (ACO)
or carnitine palmitoyl transferase 1 (CPT-1) mRNA lev-
els (Table 5).
DISCUSSION
Our study was in agreement with earlier studies that
have demonstrated increased incidence of age-related
glomerulosclerosis in rats and mice [29, 30]. Histologic
examination of in vivo perfused kidney sections demon-
strated that the age-related increase in PAS staining was
first evident at 12 months of age and then there was a
further age-related increase in PAS staining. Electron
microscopy of parallel kidney sections indicated similar
age-related glomerular changes and also age-related in-
crease in glomerular basement thickness and podocyte
width. Immunofluorescence microscopy of kidney sec-
tions also indicated an age-related increase in type IV
collagen and fibronectin accumulation, which paralleled
the finding with PAS staining.
The finding of age-related alteration in podocyte struc-
ture and increased foot process thickness in our study
was in agreement with the reported literature. In the
puromycin aminonucleoside–induced nephrosis model,
podocytes showed effacement, pseudocysts, detachment
from the glomerular basement membrane, and decreased
anionic charge, resulting in proteinuria [31]. It has
also been shown that in Milan normotensive rats, in
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A B C
Fig. 2. Transmission electron microscopy of
3-month-old (A), 12-month-old (B), and 23-
month-old (C) mice. There was an age-related
increase in glomerular basement membrane
thickness, as well as podocyte width. Increas-
ing podocyte effacement was evident in the
12-month-old and 23-month-old mice.
which glomerulosclerosis and interstitial fibrosis devel-
oped with age in the absence of systemic hypertension,
podocyte damage occurred as early as 3 months. The dam-
age became more widespread with increasing age, culmi-
nating in a loss of podocytes, and sclerotic glomeruli [32].
In the fa/fa Zucker rat (a model of type 2 diabetes), the
pathologic lesion of focal segmental glomerulosclerosis
was associated with podocyte foot process effacement,
pseudocyst formation, detachment from the basement
membrane, and lipid droplet accumulation within the
podocyte [33, 34]. In terms of human disease, podocyte
abnormalities have been implicated in the nephropathy
of type 1 diabetes mellitus [35], type 2 diabetes mellitus
[36, 37], focal segmental glomerulosclerosis [38], mini-
mal change disease [39], human immunodeficiency virus
(HIV) nephropathy [40], IgA nephropathy [41], and lu-
pus nephritis [38].
A novel finding of our study was the demonstration of
age-related increases in Oil Red O staining, which indi-
cated age-related increases in renal neutral lipid accumu-
lation. Quantitative assays of lipid extracts from kidney
indicated that the increases in Oil Red O staining cor-
responded to significant age-related increases in renal
triglyceride and cholesterol content. These changes were
seen both during fasting and postprandial conditions in-
dicating that the changes could not be merely ascribed to
alterations in the feeding cycle.
Because SREBP-1 and SREBP-2 are master regulators
of fatty acid and cholesterol metabolism [42–44], respec-
tively, we determined if there were age-related alterations
in kidney SREBP-1 and SREBP-2 expression. We found
that in nuclear extracts from the kidney there were signif-
icant age-related increases in the cleaved active nuclear
form of SREBP-1 and SREBP-2.
We next examined the expression of key SREBP-1 tar-
get enzymes that mediate fatty acid synthesis. We found
that there was an age-related increase in ATP citrate lyase
activity, a key enzyme that mediates increased fatty acid
synthesis and results in increased triglyceride synthesis.
Because triglyceride accumulation can also be mediated
by decreased fatty acid oxidation, we also measured the
mRNA levels of two key enzymes that mediate fatty acid
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Fig. 3. Basement membrane thickness (A) and podocyte width (B)
of 3-month-old, 12-month-old, and 23-month-old mice. Both basement
membrane thickness and podocyte width increased in an age-dependent
manner (P < 0.0001 for trend of increase in both basement membrane
thickening and podocyte width thickening). Comparisons of individual
ages revealed significant differences between 3 months vs. 12 months
and 23 months, and 12 months vs. 23 months for basement membrane
thickness, and between 3 months vs. 23 months and 12 months vs.
23 months for podocyte width.
oxidation. We found no age-related changes in ACO or
CPT-1 mRNA levels, indicating no age-related decreases
in fatty acid oxidation. These studies therefore suggested
that increased age-related fatty acid synthesis rather than
decreased fatty acid oxidation mediated the age-related
increase in triglyceride accumulation in the kidney. As
reported recently, in models of renal tubular injury re-
nal triglyceride accumulation can also be mediated by
increased fatty acid uptake via the fatty acid binding pro-
tein or decreased degradation via decreased lipase activ-
ity [45]. These pathways need to be elucidated in future
studies.
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Fig. 4. Immunofluorescence staining of renal
cortex for type IV collagen in 3-month-old
(A), 6-month-old (B), 12-month-old (C), 19-
month-old (D), and 23-month-old (E) mice.
There was increased type IV collagen deposi-
tion with age.
D E
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Fig. 5. Immunofluorescence staining of re-
nal cortex for fibronectin in 3-month-old (A),
6-month-old (B), 12-month-old (C), 19-
month-old (D), and 23-month-old (E) mice.
There was increased glomerular fibronectin
deposition with age.
We also examined the expression of key SREBP-2 tar-
get enzymes that mediate cholesterol synthesis and/or
cholesterol uptake. We found that there was an age-
related increase in HMG-CoA reductase mRNA and pro-
tein abundance, a key enzyme that mediates increased
cholesterol synthesis, and mRNA level of LDL receptor,
which mediates cholesterol uptake. Because cholesterol
accumulation can also be mediated by decreased choles-
terol efflux [46, 47], we also measured the mRNA lev-
els of two key proteins that mediate cholesterol efflux.
We found no age-related decrease in SR-B1 mRNA level
but a significant age-related increase in ABCA1 mRNA
level. These studies therefore suggested that increased
age-related cholesterol synthesis and uptake rather than
decreased cholesterol efflux mediated the age-related in-
crease in cholesterol accumulation in the kidney.
The regulation of SREBP expression in the kidney
has not been well described. However, studies in other
organ systems have generated a number of possible can-
didates involved in SREBP regulation. Previous stud-
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Fig. 6. Urinary protein excretion for the different ages of mice, ex-
pressed as urinary albumin to creatinine ratio. There was a significant
age-related increase in urinary protein excretion.
ies in the liver have demonstrated that SREBP-1c and
SREBP-2 appear to be subjected to transcriptional regu-
lation, whereas SREBP-1a appears to be constitutively
expressed at low levels [48]. Excess insulin stimulates
2616 Jiang et al: Renal lipid and SREBPs in age-related nephropathy
3 m 6 m 12 m 19 m 23 m
3 m 6 m 12 m 19 m 23 m
12
10
8
6
4
2
0
12
10
8
6
4
2
0
R
en
al
 tr
ig
lyc
er
id
e
(µg
/m
g 
pr
ot
ei
n)
R
en
al
 tr
ig
lyc
er
id
e
(µg
/m
g 
pr
ot
ei
n)
14
B
A
Fig. 8. Renal triglyceride content of mice from different age groups.
(A) Fasting mice. The mice showed a statistically significant increase
in renal triglyceride content as a function of aging (P for trend <0.01).
Comparisons of individual ages revealed significant differences between
3 months vs. 12, 19, and 23 months, 6 months vs. 19 and 23 months, and
12 months vs. 19 and 23 months. (B) Refed mice. The mice showed a
statistically significant increase in renal triglyceride content as a function
of aging (P for trend <0.01). Comparisons of individual ages revealed
significant differences between 3 months vs. 19 and 23 months, 6 months
vs. 19 and 23 months, and 12 months vs. 19 and 23 months.
fatty acid synthesis in the liver in periods of carbohy-
drate excess. Studies in hepatocyte cell culture [49, 50]
showed that treatment with insulin increased SREBP-
1c mRNA. Fasting/refeeding studies showed that the
amount of SREBP-1c in liver depended on the state of
feeding. Fasting decreased whereas refeeding increased
liver SREBP-1c, respectively. This paralleled the changes
in insulin secretion [44]. Studies have also suggested that
increased insulin levels or changes in nutritional status
from fasting to fed also upregulated SREBP-1c mRNA
levels in other organs, such as skeletal muscle [51, 52] and
adipose tissue [53, 54]. In addition, streptozotocin treat-
ment (which abolishes insulin secretion) led to a fall in
SREBP-1c mRNA in the liver, which was reversed upon
exogenous treatment with insulin [50]. Interestingly, our
laboratory has found the opposite response in the kidneys
of streptozotocin-treated mice, suggesting differential or
tissue-specific regulation of SREBP-1 in these two organs
[15].
Leptin deficiency has recently been implicated as a po-
tential mediator of increased SREBP-1c in adipose tissue
[55]. In leptin-deficient ob/ob mice, an increase of liver
SREBP-1c has been reported [56], although these ani-
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Fig. 9. Renal cholesterol content of mice from different age groups.
(A) Fasting mice. The mice showed a statistically significant increase
in renal cholesterol content as a function of aging (P for trend < 0.01).
Comparisons of individual ages revealed significant differences between
3 months vs. 12, 19 and 23 months, and 6 months vs. 12, 19 and 23 months.
(B) Refed mice. The mice showed a statistically significant increase in
renal cholesterol content as a function of aging (P for trend < 0.01).
Comparisons of individual ages revealed significant differences between
3 months vs. 12, 19, and 23 months, 6 months vs. 12, 19, and 23 months,
and 12 months vs. 23 months.
mals tended to be hyperinsulinemic as well, making it
difficult to ascribe the increase in SREBP solely to the
leptin resistance per se.
Recently, tumor necrosis factor-a (TNF-a) and in-
terleukin (IL)-1b have been demonstrated to increase
nuclear SREBP-1 protein in mesangial cell culture by
increasing SREBP cleavage activating protein (SCAP)
mRNA expression [57]. Other potential mediators of in-
creased SREBPs include IL-6 [58], and growth factors
such as epidermal growth factor (EGF) [59].
We propose that the age-related increases in renal
SREBP-1 and SREBP-2 expression and the resultant in-
creases in renal triglyceride and cholesterol content me-
diate the age-related glomerulosclerosis. This proposal is
supported by several lines of evidence.
In SREBP-1a transgenic mice that overexpressed the
SREBP-1a transgene in the kidney, in the absence of any
increases in serum glucose, triglyceride, or cholesterol,
there was a significant increase in renal lipid deposits and
an increase in renal triglyceride content, which was as-
sociated with glomerulosclerosis and proteinuria, resem-
bling the renal pathology seen in the diabetic and aging
kidney [15].
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Fig. 10. Nuclear sterol regulatory element-binding proteins (SREBP-
1) protein levels in kidney tissue for each age group. (A) Fasting mice.
There was an age-related increase in the amount of renal nuclear
SREBP-1 protein (P for trend < 0.01). Comparisons of individual ages
revealed significant differences between 3 months vs. 12 and 23 months,
and 12 months vs. 23 months. (B) Refed mice. There was an age-related
increase in the amount of renal nuclear SREBP-1 protein (P for trend
< 0.01). Comparisons of individual ages showed significant differences
between 3 months vs. 12 and 23 months, and 12 months vs. 23 months.
In addition, renal glomerular and tubular disease oc-
curred in a number of animal and human conditions
with primary alteration in lipid metabolism, including
in the apolipoprotein E (ApoE) knockout mice [60],
in human subjects with lecithin cholesterol acyltrans-
ferase (LCAT) deficiency [61], in ABCA1 knockout mice,
a murine model of Tangiers disease and familial high-
density lipoprotein (HDL) deficiency, with defects in
ABCA1 and HDL mediated reverse cholesterol trans-
port [62], in Fabry disease, an X-linked recessive inborn
error of glycosphingolipid catabolism resulting from defi-
cient activity of the lysosomal hydrolase a-galactosidase
A [63], and in congenital and acquired lipodystrophy [64].
There is also increasing evidence that inhibition
of cholesterol synthesis by HMG-CoA reductase in-
hibitors (statins) and triglyceride synthesis by peroxisome
proliferators-activated receptor-a (PPAR-a) agonists (fi-
brates) protected against diabetic and nondiabetic renal
disease [65, 66]. A recent meta-analysis of several small
scale interventional studies in diabetic and nondiabetic
human subjects with glomerulosclerosis and proteinuria
in fact indicated that long-term treatment with statins
and/or fibrates significantly prevent the decline in GFR
[67].
The mechanisms by which lipids mediate glomeru-
losclerosis are not completely established. In the SREBP-
1a transgenic mouse we have found increased renal
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Fig. 11. Nuclear sterol regulatory element-binding proteins (SREBP-
2) protein levels in kidney tissue for each age group. (A) Fasting mice.
There was an age-related increase in the amount of renal nuclear
SREBP-2 protein (P for trend < 0.01). Comparisons of individual ages
showed significant differences between 3 months vs. 12 and 23 months,
and 12 months vs. 23 months. (B) Refed mice. There was an age-related
increase in the amount of renal nuclear SREBP-2 protein (P for trend
< 0.01). Comparisons of individual ages showed significant differences
between 3 months vs. 12 and 23 months, and 12 months vs. 23 months.
250
200
150
100
50
0
H
M
G
-C
oA
 re
du
ct
as
e 
pr
ot
ei
n
(%
 of
 3 
m)
3 m 12 m 23 m
Fig. 12. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reduc-
tase protein abundance for each 3, 12, and 23-month old mice. There was
an age-related increase in HMG-CoA reductase protein levels (P for
trend < 0.01). A comparison of individual ages showed significant dif-
ferences between 3 months vs. 12 and 23 months.
expression of TGF-b and VEGF resulting in increased
expression of type IV collagen and fibronectin, glomeru-
losclerosis, and proteinuria [15]. In addition, cell cul-
ture studies have shown that in mesangial cells LDL or
VLDL induced up-regulation of expression of TGF-b
[68], plasminogen activator inhibitor-1 (PAI-1) [69], and
monocyte chemoattractant protein-1 (MCP-1)[70], and
2618 Jiang et al: Renal lipid and SREBPs in age-related nephropathy
Table 5. mRNA level of enzymes involved in lipid metabolism in the
kidneys
3 months old 12 months old 23 months old
Fatty acid synthesis
SREBP-1c 17.54 ± 7.53 34.75 ± 8.14 47.07 ± 11.01a
Fatty acid oxidation
ACO 149.37 ± 18.19 137.73 ± 25.04 112.17 ± 20.12
CPT-1 8.32 ± 3.29 10.43 ± 2.28 9.21 ± 2.04
Cholesterol synthesis
HMG-CoA 37.04 ± 6.67 45.65 ± 11.45 55.20 ± 5.13a
reductase
Cholesterol efflux
ABCA1 1.66 ± 0.21 1.89 ± 0.32 3.27 ± 0.63a
SR-B1 3.45 ± 0.80 3.18 ± 0.64 3.12 ± 0.19
Cholesterol uptake
LDL receptor 76.52 ± 30.80 76.70 ± 24.31 198.84 ± 47.26a,b
Abbreviations are: ACO, acetyl coenzyme A oxidase; CPT-1, carnitine palmi-
toyltransferase I; HMG-CoA reductase, 3-hydroxy-3-methylglutaryl coenzymeA
reductase; ABCA1, ATP-binding cassette A-1; SR-B1, scavenger-receptor class
B, type 1; LDL receptor, low-density lipoprotein receptor.
Values reported as mean ± SEM (arbitrary unit) of six samples.
aP < 0.05 vs. 3 months; bP < 0.05 vs. 12 months.
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Fig. 13. Adenosine triphosphate (ATP) citrate lyase activity for each
age group of mice. There was an increase in ATP citrate activity up to
19 months, and then a decrease was seen at 23 months. The increas-
ing trend was significant (P = 0.0022). Comparisons of individual ages
showed significant differences between 3 months vs. 12 and 19 months,
and 6 months vs. 12 and 19 months.
accumulation of extracellular matrix proteins [71], indi-
cating a direct role for lipids in activating the mediators
of glomerulosclerosis.
Of course as elegantly shown by Johnson, Stahl and
Zager [45], Zager et al [46], and Johnson, Yabu, and Zager
[47], the possibility also exists that age-related renal in-
jury per se can activate the lipid metabolism pathways
rather than the alterations in renal lipid metabolism me-
diating the age-related renal disease. However, we did
provide evidence that there was age-related intricate reg-
ulation of renal lipid metabolism that resulted in net re-
nal triglyceride and cholesterol accumulation, and that
increased activity of SREBP per se can induce glomeru-
losclerosis and proteinuria [15].
CONCLUSION
Our results indicated that there was an age-related in-
crease in renal expression of SREBP-1 and SREBP-2
with resultant increases in lipid synthesis and triglyceride
and cholesterol accumulation in the kidney. Because
we have previously shown that increased expression
of SREBPs in the kidney per se resulted in glomeru-
losclerosis and proteinuria, our data suggested that in-
creased SREBPs expression resulting in increased renal
lipid accumulation plays an important role in age-related
nephropathy.
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